We show that on-treatment change in GZMB expression is a dynamic biomarker of nivolumab in ccRCC, and increase in TCF7+CD8+ T cells and B cells also correlated with response in our cohort. This evidence concerns the gene TCF7 and nonpapillary renal cell carcinoma.